Bellerophon Therapeutics, which is developing nitric oxide-based
therapies for cardiopulmonary diseases, filed on Tuesday with the SEC to
raise up to $69 million in an initial public offering.
Bellerophon was spun out of Ikaria in February 2014 as a special dividend to existing stockholders, shortly before Ikaria's non-biotech business was acquired by Madison Dearborn for $1.6 billion. Ikaria had originally intended to go public in November 2010 but withdrew its offering.
The Hampton, NJ-based company, which was spun out of Ikaria in 2014, plans to list on the NASDAQ under the symbol BLPH. Bellerophon Therapeutics initially filed confidentially on May 14, 2014. Leerink Partners and Cowen & Company are the joint bookrunners on the deal. No pricing terms were disclosed.
Source: Renaissance Capital - manager of IPO-focused ETFs.
Bellerophon was spun out of Ikaria in February 2014 as a special dividend to existing stockholders, shortly before Ikaria's non-biotech business was acquired by Madison Dearborn for $1.6 billion. Ikaria had originally intended to go public in November 2010 but withdrew its offering.
The Hampton, NJ-based company, which was spun out of Ikaria in 2014, plans to list on the NASDAQ under the symbol BLPH. Bellerophon Therapeutics initially filed confidentially on May 14, 2014. Leerink Partners and Cowen & Company are the joint bookrunners on the deal. No pricing terms were disclosed.
Source: Renaissance Capital - manager of IPO-focused ETFs.
Blogger Comment
Facebook Comment